The inhibitory effect of ddC on human immunodeficiency virus replication diminishes in cells that are chronically exposed to the drug

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue 2, 1997, Pages 113-119

  Brandi, G ^a   Puddu, P ^b   Casabianca, A ^a   Cianfriglia, M ^b   Magnani, M ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

cellular resistance; ddC; HIV; nucleoside analogues

Indexed keywords

CD4 ANTIGEN; ZALCITABINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 0031056876     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029700800205     Document Type: Article

References (36)

1. Anderson S, Bankier AT, Barrell BG, De Bruijn MHL, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreirer PH, Smith AJH, Staden R & Young IG (1981) Sequence and organization of human mitochondrial genome. Nature 290: 457-465.
2. Aukrust P, Svardal MA, Muller F, Lunden B, Berge RK, Ueland PM & Froland SS (1995) Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection. Blood 86: 258-267.
3. Avramis VI, Kwock R, Solozzano MM & Gomperts E (1993) Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/ AZT-100) and in pediatric patients with HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 6: 1287-1296.
4. Beutler EMD (1984) Reduced glutathione. In Red Cell Metabolism: A Manual of Biochemical Methods. Edited by Grune X & Stratton Y. Orlando: Academic Press, pp. 131-134.
5. Broder S (1990) Dideoxycytidine (ddC): a potent antiretroviral agent for human immunodeficiency virus infection. American Journal of Medicine 88: 1S-7S.
6. Chen CH & Cheng YC (1989) Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti human immunodeficiency virus compound 2′,3′-dideoxycytidine. Journal of Biological Chemistry 264: 11934-11937.
7. Chen CH & Cheng YC (1992) The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound 2′3′-dideoxycytidine. Journal of Biological Chemistry 267: 2856-2859
8. Cianfriglia M, Willingham MC, Tombesi M, Scagliotti EV, Frasca G & Chersi A (1994) P-glycoprotein epitope mapping. Identification of a linear human specific epitope in the fourth loop of the P-glycoprotein extracellular domain by MM4.17 murine monoclonal antibody to human multi drug-resistant cells. Journal of Cancer 56:153-160.
9. Cinatl J Jr, Cinatl J, Weber B, Rabenau H, Weissflog A, Mainke M, Kornhuber B & Doerr HW (1993). Decreased anti-human immunodeficiency virus type-1 activities of 2′,3′-dideoxynucleoside analogs in MOLT-4 cell sublines resistant to 2′,3′-dideoxynucleoside analogs. Acta Virologica 37: 360-368.
10. de Quary B, Malinverni R & Lauterburg BH (1992) Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. AIDS 6: 815-819.
11. Dianzani F, Antonelli O, Capobianchi MR & De Marco F (1988) Replication of human immunodeficiency virus: yield of infectious virus under single growth cycle conditions. Archives of Virology 103:127-131.
12. Dianzani F, Antonelli G, Turriziani O, Riva E, Simeoni E, Signoretti C, Strosselli S & Cianfriglia M (1994) AZT induces the expression of cellular resistance affecting its antiviral activity. AIDS Research and Human Retroviruses 10: 1471-1476.
13. Droge W, Schulze K, Mihm S, Galter D, Schenk H, Eck HP, Roth S & Gmunder H (1994) Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB Journal 8: 1131-1138.
14. Edicott JA & Ling V (1989) The biochemistry of P-glycoprotein mediated multidrug resistance. Annual Review of Biochemistry 58: 137-171.
15. Erice A & Balfour HH (1994) Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review. Clinical Infectious Diseases 18:149-156.
16. Gao W, Agbaria R, Driscoll JS & Mitsuya H (1994) Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. Journal of Biological Chemistry 269:12633-12638.
17. Hirsch MS & D'Aquila RT (1993) Therapy for human immunodeficiency virus infection. New England Journal of Medicine 328: 1686-1695.
18. Johnson MI & Hoth DF (1993) Present status and future prospectives for HIV therapies. Science 260:1286-1293.
19. Kalebic T, Kinter A, Poli P, Anderson ME, Meister A & Fauci AS (1991) Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proceedings of the National Academy of Sciences, USA 88:986-990.
20. Kellog D & Kwok S (1990) Detection of human immunodeficiency virus In PCR Protocols. A Guide to Methods and Applications. Edited by MA Innis, DH Gelfand, JJ Snisky & TJ White. San Diego: Academic Press, pp. 337-347.
21. Larder BA, Darby G & Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731-1734.
22. Lewis W & Dalakas MC (1995) Mitochondrial toxicity of antiviral drugs. Nature Medicine 1: 417-422.
23. Magnani M, Brandi G, Casablanca A, Fraternale A, Schiavano GF, Rossi L & Chiarantini L (1995a) 2′,3′-Dideoxycytidine metabolism in a new drug-resistant cell line. Biochemical Journal 312: 115-123.
24. Magnani M, Gazzanelli G, Brandi G, Casabianca A, Fraternale A, Chiarantini L & Rossi L (1995b) 2′,3′-Dideoxycytidine induced drug-resistance in human cells. Life Science 57: 881-887.
25. Meyerhas A, Vartanian J-P, Hultgren C, Plikat U, Karlsson A, Wang L, Eriksson S & Wain-Hobson S (1994) Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. Journal of Virology 68: 535-540.
26. Müller F (1992) Reactive oxygen intermediates and human immunodeficiency virus (HIV) infection. Free Radical Biology and Medicine 13:651-657.
27. Ou CY, Kwok S, Mitchell SW, Hack DH, Snisky JJ, Krebs JW, Feorino P, Warfield D & Shochetman G (1988) DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 336:295-297.
28. Pace WG & Leaf CD (1995) The role of oxidative stress in HIV disease. Free Radical Biology and Medicine 19: 523-528.
29. Popovic M, Sarngaradharan MG, Read E & Gallo RC (1984) Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
30. Reed LJ & Muench H (1938) A simple method of estimating fifty percent endpoints. American Journal of Hygiene 27: 493-497.
31. 2-secreted by monocytes and macrophages. Methods in Enzymology 105: 365-369.
32. Roeder M, Staal FJT, Raju PA, Ela SW, Herzenberg LA & Herzenberg LA (1990) Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proceedings of the National Academy of Sciences, USA 87: 4884-4888.
33. Ruiz van Harperen VWT & Peters GJ (1994) New targets for pyrimidine antimetabolites for the treatment of solid tumors. Deoxycytidine kinase. Pharmacy World and Science 16: 104-112.
34. Schreck R, Rieber P & Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO Journal 10: 2247-2258.
35. Staal FJT, Ela SW, Roederer M, Anderson MT, Herzenberg LA & Herzenberg LA (1992) Glutathione deficiency and human immunodeficiency virus infection. Lancet 339:909-912.
36. Wu S, Liu X, Solozzano MM, Kwock R & Avramis VI (1995) Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5′ end of human TK gene. Journal of Acquired Immune Deficiency Syndromes 8:1-9.